Why Biogen's Better-Than-Expected Q1 Results Weren't Good Enough
It's fair to say that Biogen (NASDAQ: BIIB) is at a pivotal point. The company built a strong multiple sclerosis franchise that's now facing intense competition. It hopes to achieve success in treating Alzheimer's disease but must first jump a major hurdle by winning U.S. Food and Drug Administration (FDA) approval.
Biogen announced its first-quarter results before the market opened on Thursday with these factors in the minds of many investors. Those results apparently didn't give investors a warm and fuzzy feeling, though: The biotech stock slipped 4% in early trading. Here are the highlights from Biogen's Q1 update.
Image source: Getty Images.
Source Fool.com
